눈물관 스텐트 튜브 시장 예측(2026-2032년)

The Lacrimal Stent Tube Market is projected to grow by USD 408.55 million at a CAGR of 11.39% by 2032.

Lacrimal Stent Tubes: Clinical Role and Market Context

Lacrimal stent tubes are used to maintain or restore tear drainage after obstruction, injury, or surgery involving the canaliculi and nasolacrimal system. Their application spans ophthalmic procedures such as treatment of nasolacrimal duct obstruction, canalicular laceration repair, and selected reconstructive interventions. Clinical selection depends on anatomy, patient age, obstruction site, procedural approach, material properties, and the required duration of intubation.

Clinical Practice Is Shifting Toward More Precise, Patient-Specific Intubation

The landscape is changing through greater emphasis on anatomical diagnosis, minimally invasive techniques, and procedure-specific device selection. Endoscopic assessment, improved imaging, and refinements in monocanalicular and bicanalicular approaches are supporting more tailored treatment pathways. At the same time, clinicians continue to balance effective drainage support with risks such as migration, irritation, infection, granuloma formation, and the need for repeat intervention. Training, postoperative monitoring, and standardized removal protocols remain important determinants of outcomes.

Artificial Intelligence Supports Diagnosis, Planning, and Follow-Up Rather Than Replacing Surgery

Artificial intelligence can contribute to lacrimal care by assisting image interpretation, identifying patterns associated with obstruction, supporting surgical planning, and organizing longitudinal follow-up data. Potential applications include analysis of dacryocystography, nasal endoscopy, and postoperative images, subject to clinical validation and appropriate governance. AI-enabled tools are most relevant as decision-support systems: they can help prioritize cases and improve documentation, but they do not remove the need for specialist examination, intraoperative judgment, informed consent, or monitoring for complications.

Regional Insights: Access, Specialist Capacity, and Surgical Infrastructure Shape Adoption

North America generally benefits from established ophthalmic infrastructure, specialist training, and access to advanced diagnostic and surgical services. Europe combines mature clinical systems with strong attention to device safety, evidence generation, and cross-border regulatory requirements. Asia-Pacific includes highly developed ophthalmic centers alongside large populations with uneven access, making affordability, local training, and scalable care pathways important. Latin America is influenced by differences in reimbursement, specialist distribution, and procurement capacity across countries. The Middle East is developing tertiary-care capabilities in selected hubs, while referral concentration and imported-device dependence remain relevant. Africa presents substantial unmet need linked to limited specialist coverage, diagnostic access, and operating-room capacity, with public-sector programs and training partnerships important to improving care.

Group Insights: Economic and Institutional Blocs Have Different Healthcare Priorities

ASEAN markets reflect varied regulatory systems, healthcare budgets, and specialist availability, creating demand for adaptable training and distribution models. BRICS members combine major urban centers with significant regional disparities in access and procurement. The European Union emphasizes harmonized safety, documentation, and clinical requirements while preserving national differences in reimbursement and service delivery. G7 countries typically have strong specialist infrastructure, although aging populations and pressure on healthcare efficiency influence clinical pathways. GCC states continue to develop advanced hospital capacity, with procurement, localization, and specialist workforce considerations shaping access. NATO members span diverse health systems, but interoperability, emergency preparedness, and resilient medical supply chains can influence institutional purchasing priorities.

Country Insights: National Differences Influence Clinical Use and Access

Australia and Canada pair advanced specialist services with geographic challenges that can affect referral and follow-up. Brazil and Mexico show strong activity in major centers alongside uneven access across regions. China and India combine expanding urban ophthalmic capacity with large populations and substantial differences between metropolitan and rural care. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established ophthalmic services, with adoption shaped by clinical guidelines, hospital procurement, reimbursement, and regulatory processes. Russia's care environment is influenced by regional variation, institutional capacity, and supply considerations. In the United States, specialist availability and procedural infrastructure are substantial, while payer requirements, ambulatory care pathways, and evidence expectations affect purchasing and use.

Actionable Priorities for Leaders in Lacrimal Stent Tube Care

Industry leaders should align product design with clearly defined indications, emphasizing atraumatic placement, secure positioning, biocompatibility, visibility during follow-up, and efficient removal. Clinical education should focus on patient selection, anatomical assessment, procedural technique, complication recognition, and postoperative care. Organizations should build evidence programs around clinically meaningful outcomes, including anatomical patency, symptom improvement, reintervention, adverse events, and pediatric or trauma-specific performance where relevant. Regional strategies should account for regulatory requirements, public procurement, specialist training, supply continuity, and affordability without compromising quality. Digital tools, including AI-assisted imaging, should be introduced only with validation, transparency, cybersecurity, and clinician oversight.

Research Methodology: Evidence-Based Review of Clinical and System Factors

This executive summary uses a structured review framework focused on the clinical role, technology trends, regional conditions, institutional groupings, and country-level healthcare factors relevant to lacrimal stent tubes. Analysis should draw on peer-reviewed ophthalmology and otolaryngology literature, clinical guidance, regulatory documents, hospital and procurement policies, epidemiological reporting, and validated device-performance evidence. Findings should be triangulated across sources, with attention to study design, patient population, intervention type, follow-up duration, complications, and applicability across healthcare settings. Because clinical practice varies by anatomy and indication, conclusions should distinguish evidence-supported findings from contextual interpretation and avoid extrapolating beyond available data.

Conclusion: Better Outcomes Depend on Fit Between Device, Technique, and Care Pathway

Lacrimal stent tubes remain an important component of surgical management for selected lacrimal drainage disorders and injuries. Progress is being driven less by a single device characteristic than by integration of accurate diagnosis, procedure-specific design, skilled placement, reliable follow-up, and appropriate removal. Regional and country differences in infrastructure, regulation, reimbursement, and specialist access will continue to shape use. Leaders who combine robust clinical evidence with training, quality assurance, equitable access, and carefully governed digital support will be best positioned to improve patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lacrimal Stent Tube Market, by Product Type

• 7.1. Introduction
• 7.2. Bicanalicular
  • 7.2.1. Crawford
  • 7.2.2. Ritleng
• 7.3. Monocanalicular
  • 7.3.1. Pigtail Monocanalicular
  • 7.3.2. Shepard Monocanalicular

8. Lacrimal Stent Tube Market, by Material

• 8.1. Introduction
• 8.2. Polyurethane
• 8.3. Silicone
  • 8.3.1. Enhanced Flexibility
  • 8.3.2. Medical Grade

9. Lacrimal Stent Tube Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Direct Sales
  • 9.2.1. Group Purchasing Organization
  • 9.2.2. Manufacturer Direct
• 9.3. Distributors
  • 9.3.1. General Distributors
  • 9.3.2. Specialty Distributors

10. Lacrimal Stent Tube Market, by Application

• 10.1. Introduction
• 10.2. Intubation
  • 10.2.1. Bicanalicular Intubation
  • 10.2.2. Monocanalicular Intubation
• 10.3. Probing
  • 10.3.1. Complex Probing
  • 10.3.2. Simple Probing

11. Lacrimal Stent Tube Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
  • 11.2.1. Hospital Affiliated
  • 11.2.2. Standalone
• 11.3. Hospitals
  • 11.3.1. Private
  • 11.3.2. Public
• 11.4. Ophthalmology Clinics
  • 11.4.1. Chain
  • 11.4.2. Independent

12. Lacrimal Stent Tube Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Lacrimal Stent Tube Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Lacrimal Stent Tube Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Aurolab
• 16.2. Becton, Dickinson and Company
• 16.3. Bess Medizintechnik GmbH
• 16.4. BVI Medical Inc.
• 16.5. Carl Zeiss Meditec AG
• 16.6. Cook Medical
• 16.7. Fruida
• 16.8. Gunther Weiss Scientific Glassblowing Co., Inc.
• 16.9. Kaneka Medical America LLC
• 16.10. Lacrimedics
• 16.11. Medline Industries LP
• 16.12. Medtronic plc
• 16.13. OASIS Medical
• 16.14. Rumex International Co.
• 16.15. Sinopsys Surgical
• 16.16. Surtex Instruments Limited
• 16.17. Walsh Medical Devices Inc.

17. Key Experts